Antibodies specific for hyperphosphorylated tau and methods of use
US-10472415-B2 · Nov 12, 2019 · US
Antibodies specific for hyperphosphorylated tau and methods of use thereof
US11111290B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11111290-B2 |
| Application number | US-201916585207-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 27, 2019 |
| Priority date | Jul 12, 2016 |
| Publication date | Sep 7, 2021 |
| Grant date | Sep 7, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
First claim
Opening claim text (preview).
What is claimed is: 1. A humanized monoclonal antibody comprising: (a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:31; (b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4; (c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5; (d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6; (e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7; and (f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:39. 2. The antibody according to claim 1 , comprising: (a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO: 3; (b) a Light Chain CDR2 having the amino acid of SEQ ID NO:4; (c) a Light Chain CDR3 having the amino acid of SEQ ID NO:5; (d) a Heavy Chain CDR1 having the amino acid of SEQ ID NO:6; (e) a Heavy Chain CDR2 having the amino acid of SEQ ID NO:7; and (f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:39. 3. The antibody according to claim 1 , comprising (a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:31; (b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4; (c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5; (d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6; (e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7; (f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:8. 4. The antibody according to claim 1 , comprising: (a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:31; (b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4; (c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5; (d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6; (e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7; and (f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:39. 5. The antibody according to claim 1 , comprising: (a) a Light Chain comprising the amino acid sequence of SEQ ID NO:16; and (b) a Heavy Chain comprising the amino acid sequence of SEQ ID NO:11. 6. The antibody according to claim 1 , comprising: (a) a Light Chain comprising the amino acid sequence of SEQ ID NO:12; and (b) a Heavy Chain comprising the amino acid sequence of SEQ ID NO:24. 7. The antibody, according to claim 1 , comprising: (a) a Light Chain comprising the amino acid sequence of SEQ ID NO:16; (b) a Heavy Chain comprising the amino acid sequence of SEQ ID NO:24. 8. The antibody according to claim 1 , which specifically binds tau phosphorylated on the serine residue 396. 9. A pharmaceutical composition comprising the antibody according to claim 1 and a pharmaceutical acceptable carrier.
Assignees
Inventors
Classifications
Alzheimer · CPC title
Dementia; Cognitive disorders · CPC title
Neurological disorders, e.g. Alzheimer's disease · CPC title
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11111290B2 cover?
- The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
- Who is the assignee on this patent?
- H Lundbeck As
- What technology area does this patent fall under?
- Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).